CDNA - CareDx, Inc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

CareDx, Inc

3260 Bayshore Boulevard
Brisbane, CA 94005
United States
415-287-2300
http://www.caredxinc.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees227

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter MaagCEO & Director1.18MN/A1967
Dr. Reginald SeetoPres & Chief Bus. Officer450.87kN/A1972
Mr. Michael BellChief Financial Officer650.5kN/A1969
Dr. James P. YeeChief Medical OfficerN/AN/A1949
Ms. Sasha KingChief Commercial OfficerN/AN/A1986
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence-specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction methodology; and TruSight HLA, a high resolution solution that uses next generation sequencing methodology. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Corporate Governance

CareDx, Inc’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.